Iterum Therapeutics plc (ITRMF) Accumulated Expenses (2017 - 2025)

Iterum Therapeutics has reported Accumulated Expenses for 9 years, with the latest figure at $5.2 million in Q3 2025.

• On a quarterly basis, Accumulated Expenses rose 49.37% year-over-year to $5.2 million in Q3 2025; TTM through Sep 2025 was $5.2 million, a 49.37% increase from a year earlier, with the FY2024 full-year figure at $2.7 million, down 65.84% from the prior year.
• Accumulated Expenses was $5.2 million for Q3 2025 at Iterum Therapeutics, up from $4.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $9.0 million in Q3 2023, with the low at $1.2 million in Q4 2021.
• Average Accumulated Expenses over 5 years is $3.5 million, with a median of $3.0 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2022: Accumulated Expenses plunged 67.76% in 2021, then jumped 273.05% in 2022.
• Over 5 years, Accumulated Expenses stood at $1.2 million in 2021, then surged by 273.05% to $4.3 million in 2022, then jumped by 78.58% to $7.8 million in 2023, then sank by 65.84% to $2.7 million in 2024, then jumped by 96.76% to $5.2 million in 2025.
• The last three Accumulated Expenses figures came in at $5.2 million (Q3 2025), $4.0 million (Q2 2025), and $2.9 million (Q1 2025), per Business Quant data.